Cirrus Therapeutics is a privately held ocular immunology-focused biotech revolutionizing the treatment of age-related macular degeneration (AMD) and other chronic blinding diseases with groundbreaking cell and gene therapies to preserve sight, extend ocular healthspan, and enable a better quality of life as people age. Our lead program is a preclinical stage, novel adeno-associated virus (AAV) ocular gene therapy designed to potentially reverse an underlying cause of dry AMD: loss of IRAK-M protein, a key immune regulator expressed in retinal cells. Our investor syndicate includes ClavystBio, Polaris Partners and SEEDS.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/03/25 | $11,000,000 | Seed |
ClavystBio Polaris Partners SEEDS Capital | undisclosed |
